Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
Top Cited Papers
- 1 August 2008
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (8) , 1313-1318
- https://doi.org/10.1111/j.1538-7836.2008.03054.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- New antithrombotics in the prevention of thromboembolic diseaseEuropean Journal of Internal Medicine, 2005
- New anticoagulantsJournal of Thrombosis and Haemostasis, 2005
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2004
- The Pharmacology and Management of the Vitamin K AntagonistsChest, 2004
- Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous ThrombosisAnnals of Internal Medicine, 2004
- A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluationJournal of Thrombosis and Haemostasis, 2004
- Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary EmbolismNew England Journal of Medicine, 2003